BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 18063070)

  • 1. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
    Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
    Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Surgical strategy in the treatment of adrenal cortex cancer. Expanded and repeated interventions].
    Borrelli D; Bergamini C; Borrelli A; Reddavide S; Lassig R; Valeri A
    Ann Ital Chir; 2003; 74(3):311-7. PubMed ID: 14677288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
    Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant mitotane treatment for adrenocortical carcinoma.
    Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
    N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
    Grubbs EG; Callender GG; Xing Y; Perrier ND; Evans DB; Phan AT; Lee JE
    Ann Surg Oncol; 2010 Jan; 17(1):263-70. PubMed ID: 19851811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
    Berruti A; Fassnacht M; Haak H; Else T; Baudin E; Sperone P; Kroiss M; Kerkhofs T; Williams AR; Ardito A; Leboulleux S; Volante M; Deutschbein T; Feelders R; Ronchi C; Grisanti S; Gelderblom H; Porpiglia F; Papotti M; Hammer GD; Allolio B; Terzolo M
    Eur Urol; 2014 Apr; 65(4):832-8. PubMed ID: 24268504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note.
    Gonzalez RJ; Shapiro S; Sarlis N; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
    Surgery; 2005 Dec; 138(6):1078-85; discussion 1085-6. PubMed ID: 16360394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatment of adrenocortical carcinoma in children: data from the German GPOH-MET 97 trial.
    Redlich A; Boxberger N; Strugala D; Frühwald MC; Leuschner I; Kropf S; Bucsky P; Vorwerk P
    Klin Padiatr; 2012 Oct; 224(6):366-71. PubMed ID: 23143764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
    Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B;
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adrenocortical carcinoma.
    Decker RA; Kuehner ME
    Am Surg; 1991 Aug; 57(8):502-13. PubMed ID: 1928992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical aspects in the treatment of adrenocortical carcinomas in children: data of the GPOH-MET 97 trial.
    Hubertus J; Boxberger N; Redlich A; von Schweinitz D; Vorwerk P
    Klin Padiatr; 2012 Apr; 224(3):143-7. PubMed ID: 22504769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
    Advani A; Vaikkakara S; Gill MS; Arun CS; Pearce SH; Ball SG; James RA; Lennard TW; Bliss RD; Quinton R; Johnson SJ
    J Clin Pathol; 2008 Aug; 61(8):939-44. PubMed ID: 18515402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Lecka A; Ginalska-Malinowska M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.
    Luton JP; Cerdas S; Billaud L; Thomas G; Guilhaume B; Bertagna X; Laudat MH; Louvel A; Chapuis Y; Blondeau P
    N Engl J Med; 1990 Apr; 322(17):1195-201. PubMed ID: 2325710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
    Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
    Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
    Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
    Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
    Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.